Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yinglu Zhou

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The Journal of Pathology|February 8, 2023
Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancerWilliam Butler, Lingfan Xu, Yinglu Zhou, et al.
Oncogene|January 20, 2022
Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancerLingfan Xu, Bing Zhao, William Butler, et al.
Leukemia|January 30, 2023
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemiaChristine E Ryan, Danielle M Brander, Paul M Barr, et al.
Nature Communications|March 27, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trialRebecca L Porter, Yinglu Zhou, Nebiyat Eskndir, et al.
Blood Advances|January 1, 2024
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLLInhye E Ahn, Danielle M Brander, Yue Ren, et al.
Nature Cancer|September 6, 2022
Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistanceSu Deng, Choushi Wang, Yunguan Wang, et al.
Blood Advances|October 26, 2022
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistanceAishath Naeem, Filippo Utro, Qing Wang, et al.
Blood Advances|April 3, 2025
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemiaJames T Yoon, Yinglu Zhou, Mariia Mikhaleva, et al.
Science Translational Medicine|December 6, 2019
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancerYanjing Li, Yiping He, William Butler, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The Journal of Pathology|February 8, 2023
Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancerWilliam Butler, Lingfan Xu, Yinglu Zhou, et al.
Oncogene|January 20, 2022
Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancerLingfan Xu, Bing Zhao, William Butler, et al.
Leukemia|January 30, 2023
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemiaChristine E Ryan, Danielle M Brander, Paul M Barr, et al.
Nature Communications|March 27, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trialRebecca L Porter, Yinglu Zhou, Nebiyat Eskndir, et al.
Blood Advances|January 1, 2024
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLLInhye E Ahn, Danielle M Brander, Yue Ren, et al.
Nature Cancer|September 6, 2022
Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistanceSu Deng, Choushi Wang, Yunguan Wang, et al.
Blood Advances|October 26, 2022
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistanceAishath Naeem, Filippo Utro, Qing Wang, et al.
Blood Advances|April 3, 2025
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemiaJames T Yoon, Yinglu Zhou, Mariia Mikhaleva, et al.
Science Translational Medicine|December 6, 2019
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancerYanjing Li, Yiping He, William Butler, et al.
Pageof 2